Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Avelumab plus fluoropyrimidine-based chemotherapy as adjuvant treatment for stage III dMMR or POLE-mutant colon cancer
2017-000370-10Phase 3Unknown
- Sponsor
- Royal Marsden NHS Foundation Trust
- Start
- Jun 2018
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised trial of avelumab in colon cancer (2 arms), sponsored by Royal Marsden NHS Foundation Trust. Primary endpoint: 3-year disease-free survival. Status: unknown.
02
Drugs
avelumab
03
Conditions
colon cancer
Beyond the preview
Go deeper on 2017-000370-10.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-000370-10.